TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

TTENK/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Options calculator
  • Leaderboards
  • Insider trades
  • 13F funds
  • Groups
  • Trending
  • News

More

  • Pricing
  • Feedback
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice.TENK is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities TENK rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. TENK/calls is an independent service and is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Pulling SEC filings + quote and writing the call…

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback
← New search
Home›Stocks›ULTA
ULTA logo

ULTA

Ulta Beauty, Inc.

Next earnings Aug 26, 2026 · consensus $6.26 EPS, $3.04B rev

Last earnings -1.2% on 2026-06-02

Buy
$461.33
▲ +0.48%
$461.33▼ -1.39%
over 1Y
L $450.75H $706.82
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+0.5%
1W-5.0%
1M-6.8%
3M-14.2%
YTD-25.6%
1Y-1.4%
OverviewFinancialsValuationQualityTimelineFilings
Rating
Buy
Quality
B-
Valuation
Overvalued
Filings
Watch
Buy
Conviction
Horizon
Medium (3–12mo)
12-mo target
$•••
Street · 34 analysts
Buy

Best-in-class beauty retailer at a cheap 17.8x with 41% ROE; margin slippage is the offset, valuation does the work.

Revenue (FY2026) $12.4B · FY2026

The read

The fundamentals carry the rating, but the price is rich (~22% above our fair-value estimate) — a quality-at-a-price call. The case rests on the business, not the entry; patient buyers may wait for a pullback.

Ulta Beauty is a dominant US beauty specialty retailer (1,591 stores as of January 31, 2026) trading at a notably undemanding valuation. At $456.13 the stock is just 17.8x FY diluted EPS of $25.64 and 1.6x sales — cheap for a business earning a 41.1% return on equity. FY2026 revenue grew 9.7% to $12.4B, extending a multi-year growth record (from $8.63B in FY2022), and gross profit rose 10.4% to $4.85B with a healthy 39.1% gross margin.

The blemish is profitability: net income fell 4.0% to $1.15B and operating income slipped 2.0% to $1.53B, so operating margin (12.4%) and net margin (9.3%) are off prior peaks even as the top line grew. Diluted EPS still rose 1.2% to $25.64, helped by a 3.5% reduction in the share count via $901M of buybacks — capital discipline that supports per-share value even when net income dips. Operating cash flow grew 12.3% to $1.50B, comfortably funding both buybacks and $435M of capex (up 16.1%) for store growth and the international Space NK footprint.

Is ULTA a buy? The one-page verdict, explained →

The options angle

model · matches our verdict
Bull call spread~60d expiry
  • Long call 460 @ ~30.31 est
  • Short call 505 @ ~13.52 est
debit $1,679max +$2,821max −$1,679BE 476.79

BUY verdict with defined risk: the short call finances part of the long one; max loss is the net debit.

Open in the calculator →

Educational template, not a trade recommendation. Strikes and premiums are Black-Scholes model estimates from the last close and 30-day realized volatility — real chains, spreads and IV will differ. Options involve substantial risk.

Financials · annual, by fiscal year

Line itemFY22FY23FY24FY25FY26
Revenue$8.63B$10.2B$11.2B$11.3B$12.4B
Gross profit$3.37B$4.04B$4.38B$4.39B$4.85B
Operating income$1.30B$1.64B$1.68B$1.56B$1.53B
Net income$986M$1.24B$1.29B$1.20B$1.15B
Diluted EPS$17.98$24.01$26.03$25.34$25.64
Net margin11.4%12.2%11.5%10.6%9.3%

10-year statements — income, cash flow, balance sheet & CSV export →

Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.

Key statistics

Valuation

Enterprise value$19.5B
EV / EBITDA10.6
EV / Sales1.6
EV / FCF18.2
P / FCF18.6
PEG (trailing)—
Earnings yield5.8%
FCF yield5.4%

Quality & risk

ROIC (est.)42.3%
Free cash flow$1.07B
Total debt$62.3M
Net cash$362M
Altman Z-Score5.83 safe
Piotroski F-Score5/8

Capital returns

Buyback yield4.5%
Dividend yield (est.)0.3%
Shareholder yield4.9%
Shares Δ YoY-3.5%

Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.

Disclosure timeline

SEC · 8-Ks + reports
Some governance/structural items recently, but no outright red flags.
  1. 8-K Officer / director change2026-06-09
  2. 8-K Earnings results2026-06-02
  3. 10-Q Quarterly report2026-06-02
  4. DEF 14A Proxy statement2026-04-22
  5. 10-K Annual report2026-03-26
  6. 8-K Earnings results2026-03-12
  7. 8-K Officer / director change2025-12-18
  8. 8-K Earnings results2025-12-04
  9. 10-Q Quarterly report2025-12-04

Recent filings

all on EDGAR ↗
4Period ending 2026-06-152026-06-16open ↗144Filing2026-06-15open ↗4Period ending 2026-06-102026-06-11open ↗4Period ending 2026-06-102026-06-11open ↗4Period ending 2026-06-102026-06-11open ↗4Period ending 2026-06-102026-06-11open ↗4Period ending 2026-06-102026-06-11open ↗4Period ending 2026-06-102026-06-11open ↗4Period ending 2026-06-102026-06-11open ↗4Period ending 2026-06-102026-06-11open ↗4Period ending 2026-06-102026-06-11open ↗S-8 POSFiling2026-06-10open ↗

Quality score

B-
ValueGrowthProfitHealthMom.
ValueA-
GrowthC-
ProfitabilityA-
Financial healthB+
MomentumF
  • ✓Revenue growing year-over-year
  • ✓Profitable (positive net income)
  • ✗Net margin above 10%
  • ✓Return on equity above 15%
  • ✓Liabilities below 2× equity
  • ✓P/E below 25

Fair value est.

$361.30

Overvalued -22% vs price

cheapfair valueexpensive

Modified Graham: EPS $25.64 × (8.5 + 1.5 × 2.9% growth) × 1.10 quality = 14.1× multiple. An estimate, not a price target.

450.7552-week706.82
Revenue
$12.4B
+9.7% YoY
Net margin
9.3%
ROE
41.1%
P/E
18.0

SEC fundamentals · FY 2026

'22'23'24'25'26

■ revenue · ■ net income, by fiscal year

Revenue$12.4B+9.7%
Net income$1.15B-4.0%
Gross profit$4.85B+10.4%
Operating income$1.53B-2.0%
Diluted EPS$25.64+1.2%
Cash & equivalents$424M-39.7%
Total assets$7.00B+16.6%
Total liabilities$4.20B+19.4%
Stockholders' equity$2.80B+12.7%
Gross: 39.1%Op.: 12.4%L/E: 1.50x

Frequently asked

Is Ulta Beauty, Inc. (ULTA) a buy?
ULTA currently carries a Buy rating with 3/5 conviction, derived from its latest SEC filings. Best-in-class beauty retailer at a cheap 17.8x with 41% ROE; margin slippage is the offset, valuation does the work.
What is ULTA's fair value?
A Modified-Graham model based on ULTA's SEC fundamentals estimates a fair value of about $361.30. It is an estimate from reported earnings, not a price target.
Is ULTA overvalued or undervalued?
Against a Modified-Graham fair-value estimate, ULTA currently appears overvalued relative to its SEC-grounded earnings power.
What is Ulta Beauty, Inc.'s quality score?
ULTA scores 65.42269670021224/100 (grade B-) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.

Sources: SEC EDGAR (CIK 0001403568, latest 10-Q filed 2026-06-02) · EODHD · Proprietary analysis · as of 6/21/2026, 8:42:05 PM.

›About this recommendation — produced by TENK/calls (tenkcalls.com), Luxembourg · not investment advice

AI-generated analysis, produced by our proprietary engine from SEC filing data.

Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jun 21, 2026, 4:42 PM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.

Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.

Insider activity

Form 4 · SEC

Last 90 days: 0 open-market buys · 1 sale

2026-06-15
MRKONIC GEORGE R JR
Director
Sell383.00 @ $475.84$182K
2026-06-10
Smith Mike C.
Director
Award404.00
2026-06-10
Nagler Lorna
Director
Award404.00
2026-06-10
MRKONIC GEORGE R JR
Director
Award404.00
2026-06-10
Landry Stephenie Lee
Director
Award404.00
2026-06-10
Halligan Catherine Ann
Director
Award404.00

Held by tracked funds

Form 13F · SEC · quarterly
D. E. Shaw & Co.146K sh$76.3M

As of each fund’s latest quarterly 13F — a delayed snapshot, not a live position. All tracked funds →

Dividends

Irregular
Yield (TTM)
—
Annual / share
—
Last ex-date
2012-03-16
Last amount
$1.00
ex 2012-03-16paid 2012-05-15$1.00

Source: EODHD. Yield = trailing-12-month dividends ÷ price.

Earnings history

beat/miss · move
2026-06-02Miss -2.1% est▼ -1.18%8-K ↗
2026-03-12Beat +8.7% est▼ -4.28%8-K ↗
2025-12-04Beat +11.8% est▼ -1.94%8-K ↗
2025-08-28—▼ -0.60%8-K ↗
2025-05-29—▲ +1.15%8-K ↗
2025-03-13—▼ -4.48%8-K ↗

Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.

Congressional trades

all activity →

1 buy · 1 sell · 2 members · last 180d

+$24.5K net boughtlast trade 109d ago
$32.5K bought$8.00K sold
2026-04-21Maria Elvira SalazarBuy$15.0K–$50.0KPTR ↗
2026-01-15Dan NewhouseSell$1.00K–$15.0KPTR ↗
2025-10-10Valerie HoyleSell$1.00K–$15.0KPTR ↗
2024-09-23Greg LandsmanSell$1.00K–$15.0KPTR ↗
2024-08-14Greg LandsmanBuy$15.0K–$50.0KPTR ↗
2023-12-11Michael Patrick GuestBuy$1.00K–$15.0KPTR ↗
2023-10-10Lois FrankelSell$1.00K–$15.0KPTR ↗
2023-05-26Dan NewhouseSell$1.00K–$15.0KPTR ↗
2023-05-26Dan NewhouseSell$1.00K–$15.0KPTR ↗
2023-05-26Dan NewhouseBuy$1.00K–$15.0KPTR ↗
2023-04-28Lois FrankelSell$1.00K–$15.0KPTR ↗
2022-08-15John CurtisSell$1.00K–$15.0KPTR ↗

Self-reported periodic transaction reports (STOCK Act). Amounts are disclosed ranges; a trade may be a spouse's. Disclosures lag the trade by up to ~45 days. Source: House Clerk + Senate eFD.

Recent news

market news →
Q1 Earnings Roundup: Best Buy (NYSE:BBY) And The Rest Of The Specialty Retail SegmentBullish
finance.yahoo.com· 2026-07-03
Ulta Beauty (ULTA) Stock Has Cash Flow Upside While Earnings Look FairBullish
finance.yahoo.com· 2026-07-03
Ulta Beauty (ULTA) Launches Bath And Body Works In More Than 600 StoresBullish
finance.yahoo.com· 2026-07-03
Q1 Rundown: Warby Parker (NYSE:WRBY) Vs Other Beauty and Cosmetics Retailer StocksBullish
finance.yahoo.com· 2026-07-03
Inside Cannes: What Executives Said About Leading in the AI EraBullish
finance.yahoo.com· 2026-07-03
Why Is Ulta (ULTA) Down 3.5% Since Last Earnings Report?Bullish
finance.yahoo.com· 2026-07-02

Vs Consumer Discretionary peers

compare →

121 tracked peers · median

TENK Score65 vs 65
Revenue growth9.7% vs 5.1%
Net margin9.3% vs 7.1%
Return on equity41.1% vs 18.9%
P/E18.0 vs 23.4
Peers
BYDEATLEVIDECKDUOLLTHFTDRRL

News sentiment

EODHD · 47d
Bullish
+0.17
vs typical · 155 articles
↑ improving

Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.